Key factors to establish the ovalbumin-induced atopic dermatitis minipig model: age and body weight

Young Kyu Kim†, JuKyung Lee‡, Hyeon-Young Kim³, Sung-Hwan Kim³, Jeong Ho Hwang¹,⁴* and Han Na Suh¹,⁴*

Abstract

Background  Given its similar structure and immune response to the human skin, porcine is a good model for dermal studies. Here, we sensitized ovalbumin (Ova) on minipig back skin for 2–4 weeks to induce chronic atopic dermatitis (AD).

Results  Gross observation, serum cytokine level, epidermal thickness, and epidermal integrity did not change after 4 weeks of Ova induction compared with the control, indicating AD modeling failure. Only the neutrophils in the blood and macrophages in bronchoalveolar lavage fluid changed slightly until 3 or 2 weeks after Ova sensitization, respectively. The successful and failed Ova-induced AD minipig models only differ in age and body weight of the minipigs. The minipigs, 12 months old with a 30-kg median weight, had a two-fold thicker dermis than minipigs 8–10 months old, with an 18.97-kg median weight, resulting in impaired Ova permeability and immune response.

Conclusion  Age and body weight are key factors that should be considered when developing an Ova-induced AD minipig model.

Keywords  Yucatan minipig, Atopic dermatitis, Ovalbumin, Age/body weight, Dermal thickness
cells, are mainly found in the dermis. Skin immunity depends on the dermal blood vessels and lymph nodes in the dermis because of the easy recruitment of immune cells during disease conditions.

Atopic dermatitis (AD) alters the skin immunity, leading to mechanical-barrier defects. Increased irritation due to loss of barrier function is associated with a severe immune response in the skin. Thus, treatment for AD primarily focuses on restoring skin barrier function, reducing inflammation, and alleviating symptoms. Generally, topical treatments, such as corticosteroids, calcineurin inhibitors, or antibiotics combined with oral antihistamine drugs, are applied [2]. A specific cytokine blocker (monoclonal antibody) is also used to treat the AD condition [3–5]. AD is chronic and relapses easily; hence, novel effective drugs are still being developed to overcome these problems. Moreover, reliable and human mimetic animal models are essential in determining the effective drug dose without toxicity.

Rodents have been primarily used as an AD model due to their ease of handling and cost-effectiveness. Thus, methods for modeling AD in mice have been well-established, such as epicutaneous sensitization of house dust mites [6], S. aureus infection [7], food allergy [8], hapten induction [9], and genetically engineered mouse models [10, 11]. However, mouse skin differs from human or porcine skin in anatomical, physiological, and biochemical aspects. Rodents have loose subcutaneous connective tissues, while those of porcine and humans have a tight connection [12, 13]. Humans have eccrine and apocrine sweat glands, whereas porcine only has apocrine glands [14] and rodents have eccrine glands in their foot pads [15]. The epidermal thickness of humans is 50–120 μm, porcine is 30–140 μm, and rodents is 10–45 μm [13, 16]. Additionally, components of epidermal immune cells are Langerhans and αβ T cells in humans, whereas γδ dendritic epidermal T' cells are dominant in mice [17–20]. Epidermal cells are renewed every 30 days for porcine, 26–28 days for humans, and 8–10 days for rodents [21].

The similar epidermal thickness and immunological reactivity [22] of porcine to those of humans result in comparable drug absorption and metabolism [23]. These similarities make porcine a superior animal model for dermal disease studies and drug development. We previously developed a 2-week ovalbumin (Ova)-sensitized AD minipig model that is comparable with human AD, as evidenced by histological and cytokine analyses in serum and skin [24]. Considering that AD is a chronic disease, we hypothesized that prolonging the Ova sensitization mediates an accurate and precise AD minipig model. In this study, we sensitized Ova for 2, 3, or 4 weeks to optimize the AD minipig model and analyzed the histopathology and cytokine levels in serum.

Results

Establishment of chronic atopic dermatitis applying topical ovalbumin
We previously established a reliable AD minipig model [24]. However, a 2-week sensitization period is insufficient to reflect chronic AD. Thus, we extended the sensitization duration to 4 weeks. First, hematological analysis was performed to determine the immune response during AD induction. Compared with the control, the Ova-treated minipigs had higher neutrophil content until 3 weeks after sensitization.

Moreover, monocytes slightly increased until 2 weeks after sensitization (Fig. 1 A–1B), and gross observation and serum cytokine analysis were performed to confirm the AD modeling. Ova-treated skin sites did not show redness and hyperkeratosis after 4 weeks of sensitization (Fig. 1 C). Additionally, the levels of cytokine (IL-13) and immunoglobulin E did not change in serum after Ova sensitization (Fig. 1D and E). IL-4 and interferon were not detected during Ova induction (data not shown). These results indicate the failure of 4 weeks of Ova-induced AD minipig modeling.

Difference in skin layer thickness and integrity depends on age and body weight
Although the same method was used to develop the Ova-induced AD minipig model, there was still a discrepancy between the models in our previous and current studies. In this study, we utilized Yucatan minipigs 12 months old and weighing 25.37–30.74 kg (median weight: 30 kg). The control and Ova-treated skin samples showed no difference in epidermal thickness (Fig. 2 A–2B), but the Ova-treated skin had a thinner dermal layer than the nontreated skin (Fig. 2 A, 2 C) after 2 weeks of Ova induction. Also, epithelial integrity did not change after 4 weeks of the Ova induction, as identified by cell–cell junction protein levels (E-cadherin: adherent junction; Claudin-1: tight junction) (Fig. 2D and E).

The Ova induction to the Yucatan minipigs 8–10 months old and weighing 15.05–21.17 kg (median weight: 18.97 kg) increased the epidermal thickness but did not affect dermal thickness (Fig. 3 A–3 C). The protein expression levels of E-cadherin and claudin-1 decreased in the epithelium after 2-weeks Ova sensitization, indicating that the epithelial integrity decreased (Fig. 3D and E). The dermal thickness notably increased (≈ 3000 μm vs. 6000 μm; 50% increase) in the minipigs with different ages (9 vs. 12 months) and body weight (18.97 vs. 30 kg) (Fig. 2 C, 3 C). These findings suggest that age, weight, and related dermal thickness play crucial roles in the establishment of an AD minipig model.
Correlation between local and systemic inflammations

The bronchoalveolar lavage fluid was analyzed to determine the correlation between local and systemic inflammations. Alveolar macrophages increased until 3 weeks after Ova induction (Fig. 4A–4B). This result is consistent with the hematology finding that monocytes increased until 2 weeks after the Ova induction (Fig. 1A–1B). In this study, we discovered that age/body weight affects the thickness of the skin layer and Ova penetration, and it determines the success of AD porcine modeling.

Discussion

In this study, we discovered that age and body weight are the key factors that should be considered when developing an Ova-induced AD minipig model. The skin itself is a mechanical barrier, preventing the penetration of exogenous materials. The stratum corneum, an outer layer of the epidermis [25], and tight junctions comprising claudin, occludin, and ZO-1 in the interfollicular epidermis [26, 27] form the mechanical barrier and maintain skin homeostasis. Skin diseases, such as AD, impair the skin barrier and lead to allergen penetration. To establish the porcine AD model, dermal sensitization of 2,4-dinitrofluorobenzene (DNFB), a hapten, was used [28]. However, in our previous study, we discovered that DNFB severely damaged the skin barrier due to solvent (acetone:DMSO:olive oil mixture) [24]. Thus, the Ova-induced AD is a more reliable model in terms of AD mechanisms than the DNFB-induced AD model. We established a novel Ova-induced AD minipig model by applying Ova for 2 weeks [24]. However, AD is a chronic disease; thus, the duration of the immune response should be considered. In this study, we extended the Ova sensitization until 4 weeks and performed further analyses. The results showed that 4-week Ova induction did not change the skin phenotype.
(Fig. 1 C), serum cytokines (Fig. 1D and E), epidermal thickness (Fig. 2 A–2B), and epidermal integrity (Fig. 2D and E), indicating that the AD minipig modeling failed regardless of a slight increase of neutrophils in the blood (Fig. 1 A–1B). Considering these unexpected results, we dissected the reason why the AD modeling failed.

The successful and failed AD models only differed in age and body weight. The successful minipig AD modeling utilized minipigs 8–10 months old and weighing 18.97 kg (Fig. 3), whereas the failed minipig AD modeling utilized minipigs 12 months old and weighing 30 kg (Fig. 2) to induce the AD. In fact, the age of the minipig affects the skin layer thickness, especially the dermis. The stratum corneum is approximately 10-µm thick, whereas the epidermis is approximately 50–64-µm thick in Göttin gen minipigs [29]. The dermis layer thickness increases from 1.15 to 2.28 mm as the minipig ages from 1.5 to 6 months [23]. The different dermal
thickness also affects drug permeability and flux variation [23]. Considering these studies, we assume that low Ova penetration due to the thick dermis is related to the AD modeling failure. Most of the skin immune cells are distributed in the dermis [30]; hence, low Ova permeation might lead to a weak immune response. The results indicated that the 30-kg minipigs had a two-fold thicker dermal layer than the 18.97-kg minipigs (Figs. 2 and 3 C).

Another key factor affecting the establishment of a successful AD model is the sensitization skin site. A previous study discovered a significant regional difference in thickness among 11 different anatomic skin sites in porcine 3–4 months old [31]. The epidermal thickness ranges from 51.7 (lower jaw) to 91.7 μm (hind legs), depending on the site. The dermis has the thinnest depth at the outer ear and the thickest depth at the caudal back. Epidermal Langerhans cells are abundant at the mid-belly and inner ear skin. The thickness of the skin layer affects drug absorption, and immune cell distribution affects the immune reaction. Therefore, the same skin location should be used when sensitizing the skin. In this study, age/body weight strongly correlated with dermal thickness and Ova permeability. Although we failed to establish a chronic AC minipig model, we proved that age and body weight are critical factors when establishing an AD animal model.

**Conclusion**

Age/body weight and sensitization site should be prudently considered when developing an Ova-induced AD minipig model.
Methods

Animals, husbandry, and feeding
Four specific pathogen free Yucatan minipigs (Sus scrofa) aged 12 months and weighing 25.37–30.74 kg (median weight 30 kg) were supplied by Optipham (Osong, South Korea). They were transported in filter boxes and acclimatized for 7 days in the minipig facility at the Korea Institute of Toxicology. The experimental and control animals were housed individually in a perforated-bottom cage (850 x 895 x 845 mm) without bedding. Room temperature and humidity were regulated at 19 ℃-27 ℃ and 30-70%, respectively. Fluorescent lighting of 300–700 lx and air changes of 10–20 times/h were maintained. Water was provided *ad libitum*, and feed (Purina Mills, Gray Summit, MO, USA) was provided at the rate of 2% of the body weight per day.

Experimental procedure
The experiment was performed from July to August 2021. To establish the AD minipig model, back skin was shaved with clippers and sterilized with 70% isopropyl alcohol, and Ova was applied using Tegaderm (cat no. 3584; 3 M, St. Paul, MN, USA). For Ova treatment, three minipigs were sensitized with 1 mg of Ova dissolved in normal saline for 2, 3, or 4 weeks. The remaining minipig served as control. For gross observation, macroscopic images were acquired on days 1, 8, 15, 22, and 29. At the end point, the minipigs were euthanized by administering pentobarbital sodium (100 mg/kg, IV; JW Pharmaceutical, Seoul, South Korea). Skin tissue samples were obtained from all six quadrants of the treated area using a 5 mm biopsy punch for histological analysis and blood samples (10 mL) were obtained from the jugular vein for serum cytokine analysis. All the animal experiments were conducted under the Institutional Animal Care and Use Committee guideline of the Korea Institute of Toxicology (IACUC approval # 2109-0002).

Hematology
For hematology, blood was collected into EDTA-2 K tubes, and hematology parameters were measured using an ADVIA2120i hematology analyzer (Siemens, USA).

Enzyme-linked immunosorbent assay (ELISA)
Whole blood was collected into a conical tube and allowed to clot for 30 min at room temperature to analyze the cytokines in serum. Then, it was centrifuged for 10 min at 3000 rpm, and the supernatant was collected as serum. Porcine interleukin 13 (IL-13) and immunoglobulin E (IgE) were measured using ELISA (cat no. ESIL13 for IL-13; Invitrogen; and NBP275006, Novus, CO, USA for IgE) in accordance with the manufacturer’s protocols.

Masson’s trichrome staining
Masson’s trichrome staining was performed following the manufacturer’s protocol (cat no. IFU-2; ScyTek, Logan, UT, USA). Deparaffinized slides were incubated with Weigert’s iron hematoxylin, solutions of Biebrich
scarlet-acid fuchsin, phosphomolybdic-phosphotungstic acid, and aniline blue. Then, the slides were rinsed with 1% acetic acid solution. The collagen connective tissues were stained blue, the nuclei were stained dark red/purple, and the cytoplasm was stained red/pink. The samples were mounted and photographed by microscopy (Zeiss; AxioVision).

Immunohistochemistry (IHC)
The skin tissues were fixed in 10% neutral buffered formalin for overnight and then embedded in paraffin. Then, the tissue samples were sectioned (5 µm), deparaffinized, processed for antigen retrieval, blocked, and finally incubated with primary antibody, and peroxidase-conjugated secondary antibody. For peroxidase-conjugated secondary antibody, 3,3′-diaminobenzidine (DAB) substrate was used followed by hematoxylin for nuclear counterstaining. Primary antibodies against E-cadherin (Cell signaling #3195; 1:100 dilution) and Claudin-1 (Invitrogen #51-9000; 1:100 dilution) were used. The samples were mounted and photographed by microscopy (Zeiss; AxioVision).

Immune cells in bronchoalveolar lavage fluid (BALF)
Right lobes of lung were filled with PBS (total volume 500 mL) through trachea and BALF was retrieved. To determine the differential immune cell number, BALF was centrifuged (200 g, 4 °C, 10 min) onto slideglass using a Cytospin (Thermo). Then, slideglass was stained with the Diff-Quik® reagent (Sysmex Corporation, Kobe, Japan) and photographed with microscopy (Zeiss; AxioVision).

Statistical analyses
Student’s t-test was used to compare two groups. Statistical significance was considered at p < 0.05.

Abbreviations
AD  atopic dermatitis
Ova  ovalbumin

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s42826-022-00141-4.

Acknowledgements
Not applicable.

Author contribution
YK Kim, JK Lee, H Kim, and S Kim performed the experiments. HN Suh analyzed and interpreted the results. HN Suh wrote the manuscript and prepared the figures. JH Hwang provided the funding source. All authors approved the final version of the manuscript.

Funding
This work was supported by the Korea Institute of Toxicology (funding # KK-2109-01).

Data Availability
All data are included in Results.

Declarations

Competing interests
All authors have no potential conflicts of interest.

Received: 6 July 2022 / Accepted: 13 September 2022
Published online: 20 October 2022

References
1. Doebel T, Voisin B, Nagao K. Langerhans Cells - The Macrophage in Dendritic Cell Clothing. Trends Immunol. 2017;38(1):817–82.
2. Simpson EL. Atopic dermatitis: a review of topical treatment options. Curr Med Res Opin. 2010;26(3):633–40.
3. Michels GM, Walsh KF, Kryda KA, Mahabir SP, Walters RR, Hoevers JD, et al. A blinded, randomized, placebo-controlled trial of the safety of lokivetmab (277-00103269), a caninized anti-canine IL-31 monoclonal antibody in client-owned dogs with atopic dermatitis. Vet Dermatol. 2016;27(6):S05-e136.
4. Moyaert H, van Brussel L, Borowski S, Escalada M, Mahabir SP, Walters RR, et al. A blinded, randomized clinical trial evaluating the efficacy and safety of lokivetmab compared to ciclosporin in client-owned dogs with atopic dermatitis. Vet Dermatol. 2017;28(6):593-e145.
5. Souza CP, Rosychuk RAW, Contreras ET, Schissler JR, Simpson AC. A retrospective analysis of the use of lokivetmab in the management of allergic pruritus in a referral population of 135 dogs in the western USA. Vet Dermatol. 2018;29(6):489-e164.
6. Kimura M, Tsuruta S, Yoshida T. Correlation of house dust mite-specific lymphocyte proliferation with IL-5 production, eosinophilia, and the severity of symptoms in infants with atopic dermatitis. J Allergy Clin Immunol. 1998;101(1 Pt 1):84–9.
7. Laouini D, Kawamoto S, Yalcindag A, Bryce P, Mizoguchi E, Oettgen H, et al. Epicutaneous sensitization with superantigen induces allergic skin inflammation. J Allergy Clin Immunol. 2003;112(5):981–7.
8. Li XM, Kleiner G, Huang CK, Lee SY, Schofeld B, Soter NA, et al. Murine model of atopic dermatitis associated with food hypersensitivity. J Allergy Clin Immunol. 2001;107(4):693–702.
9. Man MG, Hatana Y, Lee SH, Man M, Chang S, Feingold KR, et al. Characterization of a hapten-induced, murine model with multiple features of atopic dermatitis: structural, immunologic, and biochemical changes following single versus multiple oxazolone challenges. J Invest Dermatol. 2008;128(1):79–86.
10. Chan LS, Robinson N, Xu L. Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: an experimental animal model to study atopic dermatitis. J Invest Dermatol. 2001;117(4):977–83.
11. Dillon SR, Sprecher C, Hammond A, Billsborough J, Rosenfeld-Franklin M, Presnell SR, et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol. 2004;5(7):752–60.
12. Kawamata S, Ozawa J, Hashimoto M, Kurose T, Shinozaki H. Structure of the rat subcutaneous connective tissue in relation to its sliding mechanism. Arch Histol Cytol. 2003;66(3):273–9.
13. Sullivan TP, Eggleston WH, Davis SC, Mertz P. The pig as a model for human wound healing. Wound Repair Regen. 2001;9(2):66–76.
14. Vardaxis NJ, Brans TA, Boon ME, Kreis RW, Marres LM. Confocal laser scanning microscopy of porcine skin: implications for human wound healing studies. J Dermatol Sci. 2001;24(2):193–9.
15. Quick DC, Kennedy WR, Yoon KS. Ultrastructure of the secretory epithelium, nerve fibers, and capillaries in the mouse sweat gland. Anatom Rec. 1984;208(4):491–9.
16. Meyer W, Schwarz R, Neurand K. The skin of domestic mammals as a model for the human skin, with special reference to the domestic pig. Curr Probl Dermatol. 1978;7:39–52.
17. Heath WR, Carbone FR. The skin-resident and migratory immune system in steady state and memory: innate lymphocytes, dendritic cells and T cells. Nat Immunol. 2013;14(10):978–85.

18. Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol. 2004;172(5):2731–8.

19. Pasparakis M, Haise I, Nestle FO. Mechanisms regulating skin immunity and inflammation. Nat Rev Immunol. 2014;14(5):289–301.

20. Smithey MJ, Uhrlaub JL, Li G, Vukmanovic-Stejic M, Akbar AN, Nikolich-Zugch J. Lost in translation: mice, men and cutaneous immunity in old age. Biogerontology. 2015;16(2):203–8.

21. O’Brien K, Bhatia A, Tsen F, Chen M, Wong AK, Woodley DT, et al. Identification of the critical therapeutic entity in secreted Hsp90alpha that promotes wound healing in newly re-standardized healthy and diabetic pig models. PLoS ONE. 2014;9(12):e113956.

22. Summerfield A, Hoeff J, Kreilgaard B, Madsen F, Frokjaer S. Evaluation of Gottingen minipig skin for transdermal in vitro permeation studies. Eur J Pharm Sci. 2000;11(1):14–21.

23. Qvist MH, Hoeck U, Kreilgaard B, Madsen F, Frokjaer S. Evaluation of Gottingen minipig skin for transdermal in vitro permeation studies. Eur J Pharm Sci. 2000;11(1):14–21.

24. Kim YK, Lee JI, Hwang JH, Suh HH. A Pilot Study To Establish an Ovalbumin-induced Atopic Dermatitis Minipig Model. J Vet Res. 2021;65(3):307–13.

25. Lee AV. Molecular Mechanism of Epidermal Barrier Dysfunction as Primary Abnormalities. Int J Mol Sci. 2020;21(4):1194.

26. Basler K, Bergmann S, Heisig M, Naegel I, Zorn-Kruppa M, Brandner JM. The role of tight junctions in skin barrier function and dermal absorption. J Control Release. 2016;242:105–18.

27. Yokouchi M, Kubo A. Maintenance of tight junction barrier integrity in cell turnover and skin diseases. Exp Dermatol. 2018;27(8):876–83.

28. Vana G, Meingassner JG. Morphologic and immunohistochemical features of experimentally induced allergic contact dermatitis in Gottingen minipigs. Vet Pathol. 2000;37(6):565–80.

29. Therkildsen P, Haedersdal M, Lock-Andersen J, de Fine Olivarius F, Poulsen T, Wulf HC. Epidermal thickness measured by light microscopy: a methodological study. Skin Res Technol. 1998;4(4):174–9.

30. Nguyen AV, Soulikia AM. The Dynamics of the Skin’s Immune System. Int J Mol Sci. 2019;20(8):1181.

31. Turner NJ, Pezzzone D, Badyaks SF. Regional variations in the histology of porcine skin. Tissue Eng Part C Methods. 2015;21(4):373–84.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.